Jeffrey Nakhjavan, DO
Internal Medicine · North Babylon, NYNPI 1578676136
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by GSK at 33.1% of the total. Reporting peaked in 2024 at $302 and has fallen 62.3% since, to $114 in 2025.
Across 67 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$415
- Novo Nordisk$151
- Pfizer$106
- Inspire Medical Systems, Inc.$89
- Abbott$69
- AstraZeneca$61
- plus $364 from 10 others
What the payments were for
- Food & beverage$1,255100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 23 | $415 |
| Novo Nordisk | 8 | $151 |
| Pfizer | 7 | $106 |
| Inspire Medical Systems, Inc. | 3 | $89 |
| Abbott | 4 | $69 |
| AstraZeneca | 4 | $61 |
| Hologic Sales And Service, LLC | 2 | $58 |
| Lilly USA, LLC | 3 | $58 |
| AbbVie | 4 | $56 |
| Boston Scientific | 2 | $45 |
| Corcept Therapeutics | 2 | $45 |
| Medicomp Inc | 1 | $33 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Exact Sciences | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,255 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 114 | $165,080 |
| JardianceEmpagliflozin | 56 | $80,134 |
| RybelsusSemaglutide | 34 | $66,143 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $58,078 |
| EliquisApixaban | 46 | $57,267 |
| FarxigaDapagliflozin Propanediol | 46 | $49,138 |
| MounjaroTirzepatide | 34 | $44,827 |
| TrulicityDulaglutide | 15 | $28,554 |
| XareltoRivaroxaban | 19 | $28,012 |
| CreonLipase/Protease/Amylase | 11 | $25,424 |
| LivaloPitavastatin Calcium | 13 | $7,394 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $5,761 |
| VascepaIcosapent Ethyl | 13 | $4,294 |
| Levothyroxine Sodium | 240 | $4,145 |
| Metoprolol Succinate | 277 | $4,119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $151 | $231,223148 claims |
| Boehringer IngelheimJardiance | $11 | $80,13456 claims |
| Lilly USA, LLCMounjaro, Trulicity | $58 | $73,38149 claims |
| GSKTrelegy Ellipta | $415 | $58,07856 claims |
| PfizerEliquis | $106 | $57,26746 claims |
| AstraZenecaFarxiga | $61 | $49,13846 claims |
| AbbVieCreon, Synthroid | $56 | $26,92462 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in North Babylon
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.